A spinout from the University of Oxford has launched after raising £16.5 million to target a range of cancers with its biotechnology. Yellowstone Biosciences is seeking to unlock a new class of therapeutically targetable, frequently expressed antigens with potential to significantly transform patient lives.  FTSE 250 life sciences investor Syncona committed £16.5m to fund the … Continue reading Cancer-fighting MedTech Yellowstone launches with £16.5m